# Evaluation of the Safety and Effectiveness of BELKYRA® Inj. for the Treatment of Patients With Submental Fullness Due to Submental Fat: A Postmarketing Surveillance Study in Korea

> **NCT03691415** · — · TERMINATED · sponsor: **Allergan** · enrollment: 71 (actual)

## Conditions studied

- Submental Fullness

## Interventions

- **DRUG:** BELKYRA Inj.

## Key facts

- **NCT ID:** NCT03691415
- **Lead sponsor:** Allergan
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2018-09-07
- **Primary completion:** 2020-04-14
- **Final completion:** 2020-04-14
- **Target enrollment:** 71 (ACTUAL)
- **Why stopped:** Study discontinued due to business decisions.
- **Last updated:** 2020-12-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03691415

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03691415, "Evaluation of the Safety and Effectiveness of BELKYRA® Inj. for the Treatment of Patients With Submental Fullness Due to Submental Fat: A Postmarketing Surveillance Study in Korea". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03691415. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*